Monique C. Minnema

Suggest Changes
Learn More
The efficacy of azacitidine in the treatment of high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) (20-30% blasts) has been(More)
Lenalidomide has demonstrated significant clinical activity in patients with newly diagnosed and relapsed multiple myeloma (MM). Its actions are believed to be mediated by apoptosis, anti-angiogenic(More)